MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/tid.12961

Медицинская библиотека · Transplant infectious disease : an official journal of the Transplantation Society · 2018

The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.

Webb Brandon J, Harrington Rachel, Schwartz Jason, Kammerer Jennifer, Spalding James, Lee Edward, Dodds Bart, Kaufusi Stephanie, Goodman Bruce E, Firth Sean D, Martin Greta, Sorensen Jeffrey, Hoda Daanish

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

CMV infection (CMV-I) remains an important complication of hematopoietic stem cell transplantation (HSCT).

METHODS

This was a retrospective, single-center cohort study in HSCT recipients. Primary outcomes were adjusted cost and all-cause mortality. Secondary analyses investigated CMV risk factors and the effect of serostatus.

RESULTS

Overall, 690 transplant episodes were included (allogeneic [n = 310]; autologous [n = 380]). All received preemptive CMV antiviral therapy at first detectable DNAemia. CMV-I occurred in 34.8% of allogeneic and 2.1% of autologous transplants; median time to onset was 45 days. In allogeneic HSCT recipients, the primary risk factor for CMV-I was CMV donor/recipient (D/R) serostatus. In a Markov multi-state model for allogeneic HSCT recipients, the hazard ratio for CMV-I and relapse was 1.5 (95% CI 0.8-2.8) and for CMV-I and mortality 2.4 (95% CI 0.9-6.5). In a multivariable model for all patients, CMV-I was associated with increased total cost (coefficient = 0.21, estimated incremental daily cost USD $500; P = 0.02). Cost was attenuated in allogeneic HSCT recipients (coefficient = 0.13, USD $699 vs $613, or $24 892 per transplant episode; P = 0.23). CMV disease (CMV-D) complicated 29.6% of CMV-I events in allogeneic HSCT recipients, but was not associated with an incrementally increased adjusted risk of mortality compared with CMV-I alone. CMV-I (56.4%) and CMV-D (19.8%) were significantly overrepresented in D-/R+ serostatus HSCT recipients, and mortality was higher in R+ HSCT recipients.

CONCLUSIONS

Despite early preemptive antiviral treatment, CMV-I impacts clinical outcomes and cost after HSCT, but the impact on cost is less pronounced in allogeneic HSCT recipients compared with autologous HSCT recipients.

Для цитирования: Webb Brandon J, Harrington Rachel, Schwartz Jason, Kammerer Jennifer, Spalding James, Lee Edward, Dodds Bart, Kaufusi Stephanie, Goodman Bruce E, Firth Sean D, Martin Greta, Sorensen Jeffrey, Hoda Daanish. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.. Transplant infectious disease : an official journal of the Transplantation Society. 2018. DOI: 10.1111/tid.12961.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.